Prophylactic replacement therapy is the cornerstone of treatment in severe haemophilia. Regular infusions
with clotting factor concentrate have been proven effective to prevent bleeding, subsequent (joint) damage,
and positively affect the impact of haemophilia on daily life [1]. Patients or parents of younger patients learn to infuse clotting factor concentrate in a peripheral vein (i.v.) or a central venous access device (CVAD) [2].
